Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
Key Information
Due Date: March 5, 2026
Agency: U.S. Department of Health and Human Services (HHS)
Source: Federal
Funding Category:
Health & Human Services
Funding Amount: Not Specified
Funding Type: Cooperative Agreement, Government
Match Required: No
Contact Info:
grantsinfo@nih.gov
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Overview
Specifically, the funding will support the analytical and clinical validation of a biomarker, which might be a composite biomarker or a biomarker signature. The process of validation should be carried out with a level of rigor matching the expectations described in the FDA's Biomarker Qualification Program (BQP) or as recommended by other FDA regulatory pathways. This grant represents an effort to enhance the effectiveness and reliability of therapeutic and diagnostic tools for those living with Alzheimer's disease and related dementias.
Key Dates
Open Date: August 16, 2023
Application Due Date: March 5, 2026
Estimated Award Date: Not Specified
Additional Details
Eligible Activities
- Research and Development
Eligible Applicants
- State governments
- County governments
- City, village or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Private institutions of higher education
- Small businesses